Stuart Robert's Pitt Street Report, page-2

This bit is interesting:

"Cynata is currently good value, in our opinion. We value Cynata at
$2.18 per share base case and $4.21 per share optimistic case, using
a probability-weighted DCF method. Should the GvHD study show the
clinical utility of the Cymerus technology, we see Cynata being rerated."


These guys would have to pop up as a major shareholder of CYP in the coming weeks, given the current price and their valuation?

Seems crazy that they wouldn't take their own advice.




I'll wait for the ASX announcement of a new major shareholder................waiting.............I'll come back and revisit...........